<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03823859</url>
  </required_header>
  <id_info>
    <org_study_id>EKNZ 2018-01961</org_study_id>
    <nct_id>NCT03823859</nct_id>
  </id_info>
  <brief_title>Metabolomics of Thyroid Hormones</brief_title>
  <acronym>MATcH</acronym>
  <official_title>Metabolomics of Thyroid Hormones</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ETH Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to develop a metabolome signature of thyroid hormone status. The
      metabolome signature could be useful in diagnosis and treatment of thyroid dysfunction
      diseases, especially in cases where TSH cannot be reliably used.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Hypothyroidism is a frequent endocrine disorder, where the thyroid gland does not
      produce sufficient amounts of thyroid hormones. The substitution therapy is guided by
      measurement of the pituitary gland hormone thyrotropin (TSH). Patients with central
      hypothyroidism in whom pituitary insufficiency leads to hypothyroidism, TSH cannot be used to
      guide therapy. So far there are no reliable methods for therapy control in patients with
      central hypothyroidism.

      The measurement of small endogenous metabolites might give investigators a metabolomics
      profile. This could help to discriminate between euthyroid, hypothyroid and hyperthyroid
      state and therefore could be used for diagnosis and therapy control of thyroid dysfunction
      diseases.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 12, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Metabolome signature of thyroid Hormone Status (MSTH)</measure>
    <time_frame>baseline/single visit</time_frame>
    <description>The MSTH will be tested against the current standard of diagnosis which is serum TSH level by multiple linear regression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resting energy expenditure (REE)</measure>
    <time_frame>baseline/single visit</time_frame>
    <description>Comparison of REE of healthy volunteers and Patients with thyroid dysfunction, measured by indirect calorimetry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition concerning muscle mass</measure>
    <time_frame>baseline/single visit</time_frame>
    <description>Comparison of muscle mass of healthy volunteers and patients with thyroid dysfunction, measured by DXA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition concerning fat mass</measure>
    <time_frame>baseline/single visit</time_frame>
    <description>Comparison of fat mass of healthy volunteers and patients with thyroid dysfunction, measured by DXA</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">390</enrollment>
  <condition>Central Hypothyroidism</condition>
  <condition>Hypothyroidism</condition>
  <condition>Hyperthyroidism</condition>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <description>Blood sampling (fT3, fT4, TSH, Lipids, Glucose, HbA1c)
Indirect calorimetry
Dual energy X-ray Absorptiometry (DXA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with thyroid dysfunction</arm_group_label>
    <description>Patients with Primary hypothyroidism newly diagnosed, Primary hypothyroidism substituted, hyperthyroidism, secondary hypothyroidism
Blood sampling (fT3, fT4, TSH, Lipids, Glucose, HbA1c)
Indirect calorimetry
Dual energy X-ray Absorptiometry (DXA)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Indirect calorimetry</intervention_name>
    <description>Resting energy expenditure</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>Patients with thyroid dysfunction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Dual energy X-ray Absorptiometry (DXA)</intervention_name>
    <description>Body composition</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>Patients with thyroid dysfunction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>fT4, fT3, TSH, HDL, LDL, triglycerides, cholesterol, HbA1c, Glucose Thyroid panel</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>Patients with thyroid dysfunction</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum and plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy volunteers will be recruited by means of advertisements (online or in the
        newspaper).

        Patients will be recruited from the endocrinology outpatient clinics of the Department of
        Endocrinology, Diabetes and Metabolism, University Hospital Basel and patients referred
        from practicing endocrinologists.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All participants:

          -  Age 18 to 80 years

          -  BMI 19 to 35 kg/m2

          -  Informed consent as documented by signature

        A) Patients with primary hyperthyroidism TSH &lt; 0.2 mIU/l and free thyroxine (fT4) &gt; 25 pM
        or fT3 &gt; 8 pM

        B) Patients with primary hypothyroidism, currently not sufficiently substituted TSH &gt; 8
        milli-International unit (mIU)/l or fT4 &lt; 10 pM

        C) Patients with diagnosis of primary hypothyroidism, sufficiently substituted Documented
        diagnosis of primary hypothyroidism Substitution with L-Thyroxin TSH in target range
        between 0.5 and 2.5 mIU/l

        D) Patients with secondary hypothyroidism Pituitary disease with documented secondary
        hypothyroidism

        Exclusion Criteria:

          -  Diabetes mellitus (HbA1c &gt;6.5%)

          -  Severe concomitant diseases: chronic heart failure, liver cirrhosis, kidney failure,
             active cancer

          -  Abuse of alcohol or illicit drugs

          -  Women who are pregnant or breast feeding

          -  Inability to follow the procedures of the study, e.g. due to language problems,
             psychological disorders, dementia, etc. of the participant

          -  Previous enrolment into the current study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Betz, PD Dr. med.</last_name>
    <role>Study Director</role>
    <affiliation>Klinik Endokrinologie, Diabetes und Metabolismus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthias Betz, PD Dr. med.</last_name>
    <phone>0041 61 556 56 54</phone>
    <email>Matthias.Betz@usb.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Claudia Maushart, Dr. med.</last_name>
    <email>claudia.maushart@usb.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Basel, Department of Endocrinology</name>
      <address>
        <city>Basel</city>
        <state>BS</state>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias J Betz, MD</last_name>
      <phone>0041 61 265 5078</phone>
      <email>matthias.betz@usb.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 28, 2019</study_first_submitted>
  <study_first_submitted_qc>January 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2019</study_first_posted>
  <last_update_submitted>April 3, 2020</last_update_submitted>
  <last_update_submitted_qc>April 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypothyroidism</keyword>
  <keyword>Metabolomics</keyword>
  <keyword>Thyroid Hormones</keyword>
  <keyword>Hyperthyroidism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypothyroidism</mesh_term>
    <mesh_term>Hyperthyroidism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

